HealthEconomics.com | A Scientist.com Company’s Post

Attended a very interesting talk on how to reuse clinical trial data after submission. There is immense potential in this approach, especially when looking at safety signals/clinical efficacy in sub-populations such as severe patients for market access and looking for correlations/end points within the trial populations or even within a drug class. A big thank you to Capish and Medicon Village for organizing such an insightful event! #clinicaltrials #healthcare #datareuse

Real World Evidence has emerged as a credible source of valuable data that can play a pivotal role in healthcare decisions and drug development. Data generated from #RealWorldEvidence, when integrated into various aspects of #healthcare like research, policy, and clinical decision-making, can help in accelerated drug development and improved patient care by providing a more holistic view of treatment effectiveness and treatment outcomes. Interested in finding out how Actu-Real's Real World Data Evidence Services can help you? Click here: https://lnkd.in/dvePtiSE   #ActuReal #RWE #RealWorldEvidence #DrugDevelopment #Healthcare

🔍 The MPE Navigator is designed with patients and caregivers in mind, offering a user-friendly experience that is easy to navigate. Patient organisations and advocates can also use the Navigator to drive patient-centred healthcare and promote international cooperation in advancing drug development and clinical research. Visit the MPE Navigator to learn more here: https://lnkd.in/dDRHsv2Z #MPENavigator #ClinicalTrials #Myeloma #ALAmyloidosis

Therapeutic expertise is not just about the indication, its understanding how healthcare’s delivered, how patients have access to clinical trials, and last but not least, what goes on at sites. https://lnkd.in/ej-7SYv3 #clinicaltrials #clinicalresearch

Great to see our Phase III clinical trial results for #GMRx2 featured across multiple publications in Australia.   The articles in The Herald Sun, Biotech Daily and Health Industry Hub highlighted our Phase III trial showing that GMRx2 significantly reduced #bloodpressure and improved control rates vs dual therapy, with promising results in 1,385 patients across multiple countries and potentially being able to control #hypertension for over 70% of patients. #GeorgeMedicines #Innovation #Healthcare #CardiovascularHealth #ClinicalResearch 

A recent study revealed the clinical evidence used by NICE to make decisions on medicines often lacked quality. This is concerning! To ensure patients truly benefit from new medicines, we need robust data throughout the entire process, from pre-market trials to post-market monitoring. Let's invest in stronger clinical evidence for a healthier future. #ClinicalEvidence #MedicineQuality #PatientCare #HealthcareData #MedicalResearch

Reflecting on recent advancements in clinical trial strategies, it's inspiring to see how data analytics are transforming the way we approach research, especially in rare diseases. By identifying key KOL and high-volume sites across multiple countries, we're enhancing our trial strategy and prioritizing patient safety and efficacy. It's exciting to be part of an era where data-driven insights are shaping the future of healthcare. I'm thrilled to be part of this evolving landscape in drug development. #DataAnalytics #ClinicalTrials #RareDisease #Healthcare #DrugDevelopment #patientsafety #kol

Want to know if a drug improves health outcomes? Try the “Rule of 5.” Here’s how it works: Use a minimum of 5 types of evidence in your evaluation. 1. Evidence on efficacy from clinical trials 2. Evidence on effectiveness from real-world studies 3. Evidence on important safety signals 4. Evidence on patient preferences related to the drug’s feasibility and acceptability in the intended population 5. Evidence on whether the drug represents an innovative treatment approach When you rely on limited evidence, you risk misjudging a drug’s clinical benefit. Multiple evidence sources = greater chance you accurately evaluate a drug’s clinical benefit #evidencebasedmedicine #valuebasedhealthcare #pharmacybenefits 

From providing personalized treatment plans to ensuring efficient specialty pharmacy workflows, data-driven healthcare is making monumental strides toward improving patient outcomes and accelerating drug development. But that's not all. By leveraging de-identified patient data, researchers are pioneering new therapies and enhancing disease management strategies, bringing hope to millions around the globe. However, the journey towards fully harnessing the potential of healthcare data requires overcoming challenges, such as ensuring data diversity and overcoming regulatory hurdles. #lifescaleanalytics #womenownedsmallbusiness #Data #Healthcare https://lnkd.in/gN7SX_DA

Learn about research that explores if adding a concise summary of risk information communicates drug safety information to busy healthcare providers, and supports their clinical decision-making for lactating patients in the latest Spotlight on CDER science: https://lnkd.in/gyqtKBhX